Navigation Links
MIGENIX Reports First Quarter Fiscal 2009 Financial Results
Date:9/15/2008

$ 6,817

-------------------------------------------------------------------------

Increase in cash and cash equivalents $ 1,017 $ 4,431

Cash and cash equivalents, beginning of period 2,621 2,945

-------------------------------------------------------------------------

Cash and cash equivalents, end of period $ 3,638 $ 7,376

-------------------------------------------------------------------------

About MIGENIX

MIGENIX is committed to advancing therapy, improving health, and enriching life by developing and commercializing drugs primarily in the area of infectious diseases. The Company's programs include drug candidates for: the prevention of catheter-related infections (Phase III), the treatment of dermatological diseases (end of Phase II), the treatment of chronic hepatitis C infections (Phase II and preclinical), the treatment of serious gram positive bacterial infections (preclinical) and the treatment of hepatitis B infections (preclinical). MIGENIX is headquartered in Vancouver, British Columbia, Canada. Additional information can be found at http://www.migenix.com.

FORWARD-LOOKING STATEMENTS

This news release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, and forward-looking information within the meaning of applicable securities laws in Canada (collectively referred to as "forward-looking statements"). Statements, other than statements of historical fact, are forward-looking statements. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other matters contemplated by the forward-looking statements will not occur.

Although our managemen
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Migenix averts proxy contest; reaches agreement with DJohnson holdings
2. Notice of MIGENIX General Meeting of Shareholders
3. MIGENIX Fourth Quarter and Fiscal Year 2008 Financial Results Conference Call & Webcast Notification
4. MIGENIX Corporate Update and Requisition of Special Meeting
5. Migenix Takes Operational Actions To Extend Cash Past Upcoming Key Milestones
6. MIGENIX Appoints Pieter Dorsman to Board of Directors
7. MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results
8. MIGENIX Third Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
9. MIGENIX releases CEO message #22
10. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
11. MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2014)... Canada Endoscopy Visualization Systems Market Outlook ... Canada Endoscopy Visualization Systems market. The report provides ... units) and average prices (in US dollars) within ... Endoscopy Visualization Systems and Low-End Endoscopy Visualization Systems. ... , The report also provides company shares and ...
(Date:7/25/2014)... bacteria live in each person,s digestive tract. Scientists believe ... stave off harmful infections, but their role in human ... light on the role of these bacteria, a team ... recently tracked fluctuations in the bacterial populations of two ... in the July 25 issue of the journal ...
(Date:7/25/2014)... New York (PRWEB) July 25, 2014 ... Market Research, "Biological Drugs Market - Global Industry Analysis, ... the global biological drugs market is estimated at USD ... at a CAGR of 10.1% from 2014 to 2020, ... in 2020. , The biological drugs market is witnessing ...
(Date:7/25/2014)... Livermore, California (PRWEB) July 25, 2014 ... been named to Thomson Reuters list of " The ... Pitz are part of the 3,000 researchers who were ... years to recognize those who published the highest-impact work ... numerous research papers on combustion modeling . , ...
Breaking Biology Technology:Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 3Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 5Monitoring the rise and fall of the microbiome 2Monitoring the rise and fall of the microbiome 3Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Scientists Burst onto Influential List for Combustion Research 2Scientists Burst onto Influential List for Combustion Research 3Scientists Burst onto Influential List for Combustion Research 4
... is a missing link in the capital food chain, and Bill ... devoured by it. , ,Payne, an entrepreneur-in-residence for the Kauffman ... to address the June 25 Wisconsin Alumni Research Foundation's ... the capital food chain for entrepreneurs, and he's familiar with all ...
... have pleaded guilty in Milwaukee to charges of criminal ... $6 million in counterfeit Rockwell Automation computer ... Alice Fisher for the Criminal Division and U.S. Attorney ... announced that Robert Koster of Jonesboro, Ark. pleaded ...
... print still captures the imagination of consumers - even consumers ... clearer example than Blurb . I first discussed Blurb ... than a brief PowerPoint deck. We met at ... unwound a vision for consumer-generated books that well pre-dates the ...
Cached Biology Technology:Investor warns of angel-venture funding gap 2Investor warns of angel-venture funding gap 3Two convicted of selling $6 million in counterfeit Rockwell software on eBay 2Blurb shows that print still captures imaginations 2Blurb shows that print still captures imaginations 3
(Date:7/25/2014)... factor characterized by the existence of numerous isoforms ... to the protein deeply different characteristics. NRG1 plays ... during development and the different phases occurring after ... regrowth, remyelination and target reinnervation, Researchers at the ... soluble NRG1 upregulation observed in Schwann cells immediately ...
(Date:7/25/2014)... tractography (DTT), which is derived from diffusion tensor ... motor tracts, such as the corticospinal tract, the ... The corticospinal tract is known to be a ... human brain. Several studies have reported on injury ... addition, some studies have demonstrated recovery of a ...
(Date:7/25/2014)... MOResearchers at the Stowers Institute for Medical Research ... pheromone receptors, and found pheromones crucial to triggering the ... of receptors helps a male mouse detect pheromones that ... of receptors lets him know if the female mouse ... pheromones are critical to trigger mating. Stowers, researchers believe ...
Breaking Biology News(10 mins):It takes two to court 2It takes two to court 3
... technologies are repairing the human body in ways never ... leaving an increasing population of patients who are newly ... have become a formidable clinical opponent, and foremost among ... a new text from ASM Press. "This ...
... This Christmas season, think twice about spending money on ... good, old-fashioned methodkeeping your tree in a container of ... tree green and healthy. Researchers have determined that some ... fact, in several cases the chemical retardants sped up ...
... In light of recent developments that threaten to lead to ... daily satellite images of the ice shelf available to the ... to monitor the developments as they occur. The Wilkins ... coast of the Antarctic Peninsula, has undergone many changes in ...
Cached Biology News:New text focuses on formidable opportunistic fungus 2Flame retardants prove ineffective on fresh-cut Christmas trees 2
...
...
... monoclonal [F30 P7 D7 F5] to ... tested applications). Antigen: ... Ovalbumin, corresponding to amino acids 462 ... Entrez Gene ID: 6259 ...
Pancreatic Cell Cryopreservation Medium (2X) is intended for the cryopreservation of LT2 Immortalized Pancreatic Mesenchymal Cells (SCR013) and VIT1 Primary Pancreatic Mesenchymal Cells (SCR014)....
Biology Products: